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012.12.0Abstract The assessment of myocardial viability is important in the management of patients with
coronary artery disease and left ventricular systolic dysfunction. There are several different imaging
modalities currently available for the identiﬁcation of viable myocardium: dobutamine stress echo-
cardiography, single photon emission computed tomography, delayed-enhancement cardiac mag-
netic resonance imaging, and F-18 ﬂuorodeoxyglucose positron emission tomography. The goal of
viability imaging is to determine the likelihood of recovery of systolic function after revasculariza-
tion. Positron emission tomography with F-18 ﬂuorodeoxyglucose (FDG-PET) provides informa-
tion about perfusion as well as myocardial metabolism, requires meticulous patient preparation,
and is currently the gold standard imaging modality for the assessment of myocardial viability. Via-
bility imaging for the purposes of predicting which patients will have improvement in left ventricular
systolic function is supported under current guidelines, but the results of the recent STICH-viability
substudy have created uncertainty about the incremental beneﬁt. This review article will provide a
summary of the currently available imaging modalities with an emphasis on FDG-PET and discuss
the clinical relevance of viability imaging in light of the STICH-viability substudy.
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Improvements in therapeutic options for the treatment of
acute coronary syndromes have resulted in signiﬁcant reduc-
tions in morbidity and mortality over the last several decades.
More patients are surviving the acute event due to advances in
percutaneous coronary intervention (PCI) and the develop-
ment of novel antithrombotic agents, but the number of pa-
tients that suffer from chronic left ventricular (LV) systolic
dysfunction as a result of underlying coronary artery disease
(CAD) has been steadily increasing.1,2 Over time, due to a vari-
ety of neurohormonal changes, many of these patients develop
progressive LV remodeling and signiﬁcant morbidity and mor-
tality related to congestive heart failure. It has become appar-
ent that LV systolic dysfunction associated with CAD is not
always an irreversible process, as a substantial number of pa-
tients have improvement of ejection fraction (EF) after coro-
nary revascularization.3 From this and other observations,
the concept of myocardial viability has evolved. This concept
typically refers to chronically hypocontractile tissue due to per-
sistently low nutrient coronary ﬂow that has the potential of
improving after restoration of blood supply.4
In the evaluation of patients with LV systolic dysfunction,
coronary angiography can help provide information about eti-
ology. In addition, coronary anatomy and feasibility of revas-
cularization can be determined. However, angiography does
not help predict the probability of recovery of dysfunctional
myocardium subtended by a coronary stenosis. Several imag-
ing modalities have been used in the assessment of dysfunc-
tional myocardium in order to determine the potential for
recovery of LV function after revascularization, including:
dobutamine stress echocardiography (DSE), single photon
emission computed tomography (SPECT), delayed-enhance-
ment cardiac magnetic resonance imaging (DE-CMR) and F-
18 ﬂuorodeoxyglucose positron emission tomography (FDG-
PET). The focus of the current paper will be to brieﬂy review
the imaging modalities available for determining myocardial
viability with an emphasis on FDG-PET, describe a standard
protocol for FDG-PET imaging, summarize the major trials
establishing FDG-PET as the gold standard for imaging of
myocardial viability, and ﬁnally provide comments about the
clinical relevance of myocardial viability in light of the results
of the recent STICH-viability substudy.5
2. Myocardial viability imaging
2.1. Dobutamine stress echocardiography
Dobutamine stress echocardiography relies on the demonstra-
tion of a biphasic response to increasing doses of dobutamine
to assess myocardial viability. Areas of resting hypoperfusedand hypokinetic but viable myocardium exhibit improvement
in contractility (i.e. contractile reserve) with low doses due to
the positive inotropic effects of dobutamine and the increased
coronary perfusion. However, at higher doses of dobutamine
myocardial oxygen consumption increases and ischemia devel-
ops and there is a resultant worsening of wall motion abnormal-
ities. This biphasic response is the most speciﬁc predictor by
DSE of improvement in LV function after revascularization.6
Failure of hypokinetic LV segments to improve in response to
dobutamine suggests irreversibly scarred myocardium with
low likelihood for improvement after revascularization (i.e.
nonviable). Reported sensitivities and speciﬁcities for the pre-
diction of functional recovery have ranged from 80%–85% to
85%–90%, respectively.6–8 In addition, the amount of myocar-
diumwith contractile reserve correlates reasonably well with the
expected degree of improvement in global LV systolic function
after revascularization.7–9 While other modalities for viability
imaging are performedmore frequently, DSE remains a reason-
able option; especially because of its cost-effectiveness and
excellent speciﬁcity and negative predictive value.
2.2. Single photon emission computed tomography
Single photon emission computed tomography with thallium-
201 (Tl-201) remains a commonly used imaging technique in
the United States to assess myocardial viability. Tl-201 is a
potassium analog that is taken up only by viable myocardial
cells with functioning Na+/K+-ATPase pumps. A desirable
characteristic of Tl-201 is the property of redistribution be-
tween the intracellular and intravascular space, which results
in faster washout of radiotracer from normally perfused areas
with accumulation of tracer over time in areas of relative hypo-
perfusion. This property forms the cornerstone of Tl-201 based
viability imaging. The most sensitive protocol for the detection
of viability is a stress/redistribution/reinjection sequence,
which involves typical stress imaging followed by redistribu-
tion images 3–4 h later, with subsequent reinjection of Tl-201
and delayed imaging 18–24 h later.10–12 Nonviable scar will
not have thallium uptake at stress or on redistribution/reinjec-
tion images, but viable myocardium will show an improvement
in tracer uptake over time. A number of studies have been con-
ducted to assess the accuracy of Tl-201 in predicting the recov-
ery of LV systolic function after revascularization, with quoted
pooled sensitivity and speciﬁcity of 86% and 47%, respectively
when using a stress/redistribution/reinjection protocol.8,10–14
2.3. Cardiac magnetic resonance imaging
Another technique that is becoming more frequently utilized
for viability imaging is delayed-enhancement cardiac magnetic
resonance imaging with gadolinium-based contrast agents. In
PET imaging with FDG to guide revascularization in patients with systolic heart failure 125normal myocardium, gadolinium quickly washes in and out of
the myocyte. However, conditions associated with ﬁbrosis or
excess interstitial space cause a delay in both the wash in
and wash out of gadolinium as it becomes trapped in the excess
interstitial tissue. This property forms the basis of delayed
enhancement, whereby areas of scar or ﬁbrosis appear hype-
renhanced when imaged several minutes after injection of con-
trast. Quantiﬁcation of myocardial scarring can be determined
based on the transmural extent of hyperenhancement, with full
thickness enhancement representing nonviable scar with little
chance for functional improvement, while segments with min-
imal hyperenhancement represent viable myocardial cells with
excellent chance for recovery after revascularization. Beneﬁts
of DE-CMR include the lack of ionizing radiation and the
ability to assess the transmural extent of myocardial scar.
However, it is contraindicated in many patients due to the
implantation of pacemakers/ICD’s or other metallic foreign
bodies. Also, gadolinium must be used carefully in patients
with end-stage renal disease due to the small risk of nephro-
genic systemic ﬁbrosis. DE-CMR has improved sensitivity
and speciﬁcity for the detection of viable myocardium when
compared to SPECT, and comparable sensitivity and speciﬁc-
ity compared to the gold standard of viability imaging, PET
with F-18 FDG.15–17
2.4. Positron emission tomography
Positron emission tomography differs from conventional
SPECT imaging in that the isotopes are positron-emitting
and release two photons of much higher energy (511 keV) that
travel at 180 degrees from each other. Images generated by
PET have higher temporal and spatial resolution than SPECT,
and therefore are of higher-quality and provide greater diag-
nostic accuracy. The most commonly used isotopes in PET
perfusion imaging in clinical practice are rubidium-82 and
nitrogen-13 ammonia. Nitrogen-13 ammonia is a cyclotron-
produced product, while rubidium-82 can be eluted from a
commercially available strontium-82 generator. In addition
to perfusion imaging agents, there are also several metabolic
imaging agents that allow evaluation of myocardial metabo-
lism. The most commonly used metabolic imaging agents are
F-18 ﬂuorodeoxyglucose, carbon-11 palmitate, and carbon-
11 acetate. Sequential imaging of myocardial perfusion and
metabolism can provide important information about viable,
hibernating myocardium. In areas of the world where there
is no access to rubidium-82, perfusion imaging can be obtained
with SPECT imaging and subsequent metabolic imaging with
PET.
3. F-18 ﬂuorodeoxyglucose-pet imaging of myocardial viability
In the fasting state, myocardial cells utilize free fatty acids that
have been mobilized from triglycerides as the preferred sub-
strate for metabolism. In contrast, increases in plasma glucose
and insulin levels after a meal reduce the mobilization of free
fatty acids, and myocardial cells preferentially utilize glucose
for energy production in the fed state. However, under condi-
tions of reduced myocardial blood ﬂow and therefore reduced
availability of oxygen, metabolism of free fatty acids is greatly
diminished and under these ischemic conditions myocardialcells shift to preferential glucose utilization.18 This property
can be exploited by the use of FDG-PET in the evaluation
of tissue viability.
F-18 ﬂuorodeoxyglucose is the metabolic marker used most
commonly in PET imaging for myocardial viability. FDG is a
cyclotron-produced glucose analog that undergoes positron
emission with a half-life of 110 min. It is transported across in-
tact cell membranes by the same mechanism as glucose, the
GLUT-1 and GLUT-4 transporters. Once inside the myocyte,
FDG undergoes hexokinase-mediated phosphorylation to
FDG-6-phosphate. Further metabolism of FDG-6-phosphate
is limited and it becomes trapped inside of the myocyte, per-
fectly suited for imaging regional glucose uptake by PET. Pa-
tient preparation and imaging protocols are extremely
important in ensuring the accuracy of FDG-PET viability
imaging and will be discussed in some detail.
3.1. FDG-PET protocols
Blood levels of substrate and hormones need to be closely reg-
ulated to ensure the myocyte utilization of glucose over fatty
acids. Several different options are available for patient prep-
aration for FDG imaging: fasting, glucose loading, hyperinsu-
linemic-euglycemic clamp, and Acipimox.
The most commonly used and currently recommended pro-
tocol involves either oral or intravenous glucose loading prior
to injection of FDG (see Fig. 1). The purpose of glucose load-
ing is to stimulate the endogenous release of insulin and there-
by enhance the myocyte uptake of FDG. Patients are typically
fasted for a minimum of 6 h, then given glucose loading either
orally or intravenously after determination of fasting plasma
glucose levels. Plasma glucose levels are then monitored and
supplemental insulin may be given to achieve a target glucose
level of 100–140 mg/dL at the time of FDG injection. This
technique can present challenges in patients with diabetes mel-
litus, related to inherent insulin resistance and frequently need
supplemental insulin and close monitoring of glucose levels to
ensure adequate myocyte uptake of FDG.19 Once blood glu-
cose levels are within the recommended range, injection of
FDG (typically 5–15 mCi) is given and imaged under the
PET camera 45–60 min after injection.20
Alternatively, patients can undergo FDG-PET in the fast-
ing state, which obviates the need for seemingly complicated
glucose loading schemes. However, there may be substantial
differences in regional myocardial utilization of glucose, lead-
ing to incorrect interpretation of images and overestimation of
myocardial viability.21 Thus, current recommendations advo-
cate against FDG-PET under fasting conditions.
A more technically demanding and labor-intensive ap-
proach is the hyperinsulinemic-euglycemic clamp. While this
does allow close monitoring and titration of substrate and hor-
monal levels resulting in the most consistent and high-quality
images,21,22 most laboratories do not routinely use this method
of patient preparation.
Finally, a nicotinic acid derivative not commercially avail-
able in the United States, Acipimox, stimulates myocardial
glucose utilization by inhibiting peripheral lipolysis and reduc-
ing free fatty acid levels. It is not FDA approved in the United
States, but does provide consistent image quality and has been
used with success in other parts of the world.23,24
Figure 1 Glucose loading protocol prior to the administration of FDG in non-diabetic and diabetic patients.
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Regardless of whether SPECT or PET is used for perfusion
imaging, using a sequential perfusion-metabolism approach
yields several different interpretation possibilities. Normal per-
fusion images effectively guarantee myocardial viability, and
therefore under conditions of normal perfusion it may not be
necessary to continue with metabolic imaging. Many physi-
cians prefer to obtain rest-stress images prior to metabolic
imaging for this reason. However, a pattern of normal perfu-
sion coupled with reduced FDG uptake (so-called reversed
perfusion-FDG mismatch) has been described in patients with
left bundle branch block25 and also under conditions of repet-
itive myocardial stunning.26 Areas of myocardial scar with
nonviable tissue will have a matched reduction on both perfu-
sion and metabolic images. Perfusion-metabolism mismatch––
i.e., an area with reduced perfusion associated with normal or
enhanced FDG uptake––is indicative of hibernating, viable
myocardium27 that has the potential for reversibility of dys-
function after coronary revascularization (see Fig. 2).
Centers that do not have access to PET perfusion tracers
typically use SPECT imaging for evaluation of perfusion com-
bined with FDG-PET imaging for metabolic evaluation. Com-
parison of SPECT perfusion images with PET metabolism
images should be done carefully. Many SPECT images arecreated without the use of attenuation-correction, and areas
of apparently reduced myocardial perfusion due to soft tissue
attenuation may result in the appearance of perfusion-metab-
olism mismatch and incorrect interpretation. Utilizing ECG-
gated images for assessing regional wall motion may help de-
crease the likelihood of false-positive perfusion-metabolism
mismatch.28 In addition, employment of either CT based or
line-source based SPECT attenuation correction can also re-
duce the likelihood of incorrect interpretation due to soft tissue
attenuation.
3.3. Prediction of functional recovery by FDG-PET viability
imaging
As previously stated, the ultimate purpose of imaging aimed at
detecting myocardial viability is to identify patients with LV
systolic dysfunction who will beneﬁt from revascularization,
not only in terms of improvement in regional and global LV
function, but also in improvement of symptoms, exercise capac-
ity and long-term prognosis. Numerous studies have evaluated
the accuracy of combined perfusion/metabolism FDG-PET
viability imaging in predicting regional recovery of dysfunc-
tional myocardium. Depending on the criteria used for deﬁning
reversibility and improvement, analyses have estimated the po-
sitive predictive value for predicting improvement in segmental
Figure 2 Cardiac PET images in short-axis, vertical long-axis, and horizontal long-axis demonstrating perfusion-metabolism mismatch
in the mid and basal anterior, anteroseptal, anterolateral and lateral walls consistent with myocardial viability in those territories.
Figure 3 Annual death rates for patients with and without
myocardial viability treated by revascularization or medical
therapy. Patients with viable myocardium had a signiﬁcantly lower
mortality rate after revascularization compared to those treated
medically. Patients without viable myocardium had no signiﬁcant
difference in mortality rate with revascularization compared to
medical therapy. (Adapted with permission from Allman KC,
Shaw LJ, Hachamovitch R, et al.: Myocardial viability testing and
impact of revascularization on prognosis in patients with coronary
artery disease and left ventricular dysfunction: A meta-analysis, J
Am Coll Cardiol 39:1151–1158, 2002.).
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100%, with an average positive predictive value of 74%. In
addition, the negative predictive value ranged from 67% to
100%, with an average negative predictive value of 87%.29–37Furthermore, the positive and negative predictive values of
FDG-PET in predicting improvement of global LV dysfunc-
tion––a potentially more clinically meaningful improvement––
are comparable, at 68% and at 80%, respectively.29,34,36,38,39
It also appears that patients with larger areas of hibernating
myocardium and more territory at risk derive the greatest
beneﬁt from revascularization in terms of improvement in LV
dysfunction, symptoms, and exercise capacity.38,40–43 Most
importantly, patients with ischemic but viable myocardium
have higher annualized cardiac event rates than those without
myocardial viability when treated medically in the absence of
revascularization (see Fig. 3), particularly in those with severe
LV dysfunction and large areas of viable myocardium.31,44–504. Current clinical challenges in myocardial viability imaging
The surgical treatment for ischemic heart failure (STICH)
trial51 was a recent multicenter, randomized trial that enrolled
patients with angiographic documentation of coronary artery
disease amenable to surgical revascularization and with left
ventricular systolic dysfunction (ejection fraction, 635%) to
either medical therapy alone, or medical therapy in combina-
tion with coronary artery bypass grafting (CABG). The initial
design of the study also called for all enrolled patients to have
myocardial viability imaging, but due to difﬁculty with timely
enrollment, that requirement was later dropped and myocar-
dial viability imaging became optional. Thus, there was a subset
of patients with CAD and LV systolic dysfunction that under-
went myocardial viability imaging. Unfortunately, the modal-
ity of viability imaging was either with DSE or SPECT, both
of which are inferior to PET-FDG and DE-CMR. Patients
were then classiﬁed according to prespeciﬁed thresholds as
128 J.R. McCrary et al.either having or not having evidence of myocardial viability
and randomized to receive either medical therapy alone or med-
ical therapy plus CABG. Multivariable analysis looking for a
signiﬁcant association between the presence of myocardial via-
bility and outcome found no correlation. In addition, analyses
focusing on whether the presence of myocardial viability im-
pacted the likelihood of beneﬁt from medical therapy plus
CABG vs. medical therapy alone also failed to demonstrate
an interaction with respect to death, cardiovascular death, or
the composite endpoint.5 The results of this viability substudy
were perhaps unexpected, and raised serious questions about
the utility of viability imaging in patients with CAD and LV
systolic dysfunction.
However, there are multiple limitations of the STICH-via-
bility substudy that should be considered before making ﬁrm
conclusions. First, only a very small percentage of those pa-
tients screened actually met the inclusion criteria, and as such
a very small minority of all screened patients were actually en-
rolled. In addition, viability imaging was not mandated nor
were patients randomized according to their viability results.
There were also signiﬁcant differences in baseline characteris-
tics between the patients with and without viability. Further-
more, the choices for viability imaging (SPECT and DSE)
clearly are inferior to other modalities of viability imaging,
namely DE-CMR and FDG-PET. Also, the classiﬁcation of
patients in a binary fashion as either having or not having via-
bility certainly does not take into account the extent of viabil-
ity present or the presence of stress-induced ischemia, both of
which have potential impact on the expectation for functional
improvement after revascularization. Finally, the sample size
of patients in the STICH-viability substudy with nonviable
myocardium was quite small, likely resulting in an underpow-
ered study to detect signiﬁcant differences between the two
groups. Despite these limitations, the STICH trial and the via-
bility substudy have fueled the debate over the usefulness and
appropriateness of viability imaging in patients with CAD and
LV dysfunction and did not, as was hoped, provide a deﬁni-
tive, resounding answer.
5. Conclusions
The concepts of hibernating, stunned, and viable myocardium
remain at the forefront of the debate regarding the appropri-
ateness of revascularization for patients with CAD and signif-
icant LV systolic dysfunction. Numerous studies have
evaluated this question, with the general consensus that viabil-
ity imaging for the purposes of estimating likelihood of recov-
ery of systolic dysfunction is reasonable, and current AHA/
ACC guidelines give this a class IIa recommendation.52 Several
modalities are available for imaging of viable myocardium,
with FDG-PET as the currently accepted gold standard.
FDG-PET can identify patients with LV systolic dysfunction
who may beneﬁt from revascularization, not only in terms of
improvement in regional and global LV function, but also in
improvement of symptoms, exercise capacity and long-term
prognosis. The results of the STICH-viability substudy have
called into question the incremental beneﬁt of viability imaging
in this clinical scenario. Clearly, further well conducted, ran-
domized-controlled trials are needed to deﬁnitively answer
the challenging question of which patients derive the most ben-
eﬁt from viability imaging.References
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